Answers are grounded in this paper and cite their sources.
De novo nontuberculous mycobacterial (NTM) disease after lung transplantation remains poorly characterized. We systematically reviewed its clinical features, microbiologic spectrum, treatment, and outcomes. PubMed, Embase, and Scopus were searched from inception through October 15, 2025, following PRISMA 2020 guidelines. Studies reporting de novo NTM disease after lung transplantation, distinct from pre-transplant colonization and donor-derived infection, were included. We extracted patient characteristics, NTM species, treatment, microbiologic clearance, graft outcomes, and mortality. Methodological quality was assessed using Joanna Briggs Institute critical appraisal checklists for case reports and case series and the Newcastle–Ottawa Scale for retrospective cohorts. Findings were synthesized descriptively because of clinical and methodological heterogeneity. Thirteen studies comprising 60 patients were included. Bilateral lung transplantation was performed in 41/60 patients (68.3%). Among 39 patients with available demographic data, the median age was 53 years (interquartile range [IQR], 38.5–65), and 23/39 (59.0%) were male. Sixty-one NTM organisms were reported, including one dual isolation. Mycobacterium abscessus complex/M. chelonae–abscessus group (30/61, 49.2%) and Mycobacterium avium complex (23/61, 37.7%) predominated. Median time to disease onset was 12 months (IQR, 4–24). All patients had respiratory involvement; 56/60 (93.3%) had no documented dissemination, whereas 4/60 (6.7%) had disseminated disease. Among 14 patients with reported microbiological clearance and usable duration data, median reported treatment exposure was 9.1 months (IQR, 4.8–12.0), including therapy truncated by death. Source-defined microbiologic clearance occurred in 17/25 patients (68.0%) with a reported binary outcome. Twelve-month mortality was 20/60 (33.3%), and adverse graft outcomes occurred in 13/33 patients (39.4%) with reported graft outcomes. Most studies had moderate risk of bias. Mortality and adverse graft outcomes were frequently reported among published cases of de novo NTM disease after lung transplantation. The predominance of small case reports and series, heterogeneous diagnostic and surveillance practices, and incomplete outcome reporting limit generalizability and conclusions about treatment. Prospective multicenter studies using standardized definitions and outcomes are needed. PROSPERO CRD420251170157.
No takes yet. Share an insight, caveat, or question.
Priyadarshi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: